185 related articles for article (PubMed ID: 12732670)
1. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results.
Siegel BA; Dehdashti F; Mutch DG; Podoloff DA; Wendt R; Sutton GP; Burt RW; Ellis PR; Mathias CJ; Green MA; Gershenson DM
J Nucl Med; 2003 May; 44(5):700-7. PubMed ID: 12732670
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer.
Müller C; Schibli R; Krenning EP; de Jong M
J Nucl Med; 2008 Apr; 49(4):623-9. PubMed ID: 18344429
[TBL] [Abstract][Full Text] [Related]
3. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical.
Mathias CJ; Wang S; Waters DJ; Turek JJ; Low PS; Green MA
J Nucl Med; 1998 Sep; 39(9):1579-85. PubMed ID: 9744347
[TBL] [Abstract][Full Text] [Related]
4. A kit formulation for preparation of [(111)In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical.
Mathias CJ; Green MA
Nucl Med Biol; 1998 Aug; 25(6):585-7. PubMed ID: 9751427
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical.
Wang S; Luo J; Lantrip DA; Waters DJ; Mathias CJ; Green MA; Fuchs PL; Low PS
Bioconjug Chem; 1997; 8(5):673-9. PubMed ID: 9327130
[TBL] [Abstract][Full Text] [Related]
6. Imaging tumor folate receptors using 111In-DTPA-methotrexate.
Ilgan S; Yang DJ; Higuchi T; Zareneyrizi F; Kim EE; Podoloff DA
Cancer Biother Radiopharm; 1998 Jun; 13(3):177-84. PubMed ID: 10850353
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor-associated folate receptor with an 111In-DTPA conjugate of pteroic acid.
Ke CY; Mathias CJ; Green MA
J Am Chem Soc; 2005 May; 127(20):7421-6. PubMed ID: 15898791
[TBL] [Abstract][Full Text] [Related]
8. The folate receptor as a molecular target for tumor-selective radionuclide delivery.
Ke CY; Mathias CJ; Green MA
Nucl Med Biol; 2003 Nov; 30(8):811-7. PubMed ID: 14698784
[TBL] [Abstract][Full Text] [Related]
9. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors.
Fisher RE; Siegel BA; Edell SL; Oyesiku NM; Morgenstern DE; Messmann RA; Amato RJ
J Nucl Med; 2008 Jun; 49(6):899-906. PubMed ID: 18483093
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging.
Guo W; Hinkle GH; Lee RJ
J Nucl Med; 1999 Sep; 40(9):1563-9. PubMed ID: 10492380
[TBL] [Abstract][Full Text] [Related]
11. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate.
Mathias CJ; Wang S; Lee RJ; Waters DJ; Low PS; Green MA
J Nucl Med; 1996 Jun; 37(6):1003-8. PubMed ID: 8683292
[TBL] [Abstract][Full Text] [Related]
12. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of 99mTc(CO)(3)-DTPA-folate as a folate-receptor-targeted radiopharmaceutical.
Trump DP; Mathias CJ; Yang Z; Low PS; Marmion M; Green MA
Nucl Med Biol; 2002 Jul; 29(5):569-73. PubMed ID: 12088727
[TBL] [Abstract][Full Text] [Related]
14. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
Gallup DG
Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342
[No Abstract] [Full Text] [Related]
15. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
[TBL] [Abstract][Full Text] [Related]
16. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of a 153 Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts.
Konda SD; Wang S; Brechbiel M; Wiener EC
Invest Radiol; 2002 Apr; 37(4):199-204. PubMed ID: 11923642
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging.
Wang S; Lee RJ; Mathias CJ; Green MA; Low PS
Bioconjug Chem; 1996; 7(1):56-62. PubMed ID: 8741991
[TBL] [Abstract][Full Text] [Related]
19. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
20. Immunopharmacokinetics of 111In-CYT-103 in ovarian cancer patients.
Jusko WJ; Kung LP; Schmelter RF
Targeted Diagn Ther; 1992; 6():177-90. PubMed ID: 1576345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
